Tuning Cancer Fate: the Unremitting Role of Host Immunity

Overview

Journal Open Biol

Specialties Biology
Cell Biology
Molecular Biology

Date 2017 Apr 14

PMID 28404796

Citations 22

Authors

B Cali

B Molon

A Viola

Affiliations

Soon will be listed here.

Abstract

Host immunity plays a central and complex role in dictating tumour progression. Solid tumours are commonly infiltrated by a large number of immune cells that dynamically interact with the surrounding microenvironment. At first, innate and adaptive immune cells successfully cooperate to eradicate microcolonies of transformed cells. Concomitantly, surviving tumour clones start to proliferate and harness immune responses by specifically hijacking anti-tumour effector mechanisms and fostering the accumulation of immunosuppressive immune cell subsets at the tumour site. This pliable interplay between immune and malignant cells is a relentless process that has been concisely organized in three different phases: elimination, equilibrium and escape. In this review, we aim to depict the distinct immune cell subsets and immune-mediated responses characterizing the tumour landscape throughout the three interconnected phases. Importantly, the identification of key immune players and molecules involved in the dynamic crosstalk between tumour and immune system has been crucial for the introduction of reliable prognostic factors and effective therapeutic protocols against cancers.

Citing Articles

Combining TIGIT blockade with IL-15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma.

Luo B, Sun Y, Zhan Q, Luo Y, Chen Y, Fu T Clin Transl Med. 2024; 14(1):e1553.

PMID: 38279870 PMC: 10819095. DOI: 10.1002/ctm2.1553.

Metabolic diversity of tumor-infiltrating T cells as target for anti-immune therapeutics.

Li P, Li F, Zhang Y, Yu X, Li J Cancer Immunol Immunother. 2023; 72(11):3453-3460.

PMID: 37733059 PMC: 10992207. DOI: 10.1007/s00262-023-03540-1.

The Role of Nucleases Cleaving TLR3, TLR7/8 and TLR9 Ligands, Dicer RNase and miRNA/piRNA Proteins in Functional Adaptation to the Immune Escape and Xenophagy of Prostate Cancer Tissue.

Kocic G, Hadzi-Djokic J, colic M, Veljkovic A, Tomovic K, Roumeliotis S Int J Mol Sci. 2023; 24(1).

PMID: 36613950 PMC: 9820234. DOI: 10.3390/ijms24010509.

The role of IL-35 and IL-37 in breast cancer - potential therapeutic targets for precision medicine.

Ma Y, Su H, Wang X, Niu X, Che Y, Hambly B Front Oncol. 2022; 12:1051282.

PMID: 36483045 PMC: 9723453. DOI: 10.3389/fonc.2022.1051282.

What Are the Reasons for Continuing Failures in Cancer Therapy? Are Misleading/Inappropriate Preclinical Assays to Be Blamed? Might Some Modern Therapies Cause More Harm than Benefit?.

Mirzayans R, Murray D Int J Mol Sci. 2022; 23(21).

PMID: 36362004 PMC: 9655591. DOI: 10.3390/ijms232113217.

References

Koebel C, Vermi W, Swann J, Zerafa N, Rodig S, Old L . Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450(7171):903-7. DOI: 10.1038/nature06309. View

Mackie R, Reid R, Junor B . Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med. 2003; 348(6):567-8. DOI: 10.1056/NEJM200302063480620. View

So T, Takenoyama M, Mizukami M, Ichiki Y, Sugaya M, Hanagiri T . Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res. 2005; 65(13):5945-52. DOI: 10.1158/0008-5472.CAN-04-3787. View

Porta C, Riboldi E, Sica A . Mechanisms linking pathogens-associated inflammation and cancer. Cancer Lett. 2010; 305(2):250-62. DOI: 10.1016/j.canlet.2010.10.012. View

Schneider H, Downey J, Smith A, Zinselmeyer B, Rush C, Brewer J . Reversal of the TCR stop signal by CTLA-4. Science. 2006; 313(5795):1972-5. DOI: 10.1126/science.1131078. View

Vetizou M, Pitt J, Daillere R, Lepage P, Waldschmitt N, Flament C . Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015; 350(6264):1079-84. PMC: 4721659. DOI: 10.1126/science.aad1329. View

Montagna D, Maccario R, Locatelli F, Montini E, Pagani S, Bonetti F . Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia. Blood. 2006; 108(12):3843-50. DOI: 10.1182/blood-2006-05-021535. View

Aulak K, Miyagi M, Yan L, West K, Massillon D, Crabb J . Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. Proc Natl Acad Sci U S A. 2001; 98(21):12056-61. PMC: 59826. DOI: 10.1073/pnas.221269198. View

Dunn G, Bruce A, Sheehan K, Shankaran V, Uppaluri R, Bui J . A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005; 6(7):722-9. DOI: 10.1038/ni1213. View

10.

Long K, Beatty G . Harnessing the antitumor potential of macrophages for cancer immunotherapy. Oncoimmunology. 2014; 2(12):e26860. PMC: 3902119. DOI: 10.4161/onci.26860. View

11.

Teshima T, Liu C, Lowler K, Dranoff G, Ferrara J . Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation. Cancer Res. 2002; 62(3):796-800. View

12.

Nishikawa H, Sakaguchi S . Regulatory T cells in tumor immunity. Int J Cancer. 2010; 127(4):759-67. DOI: 10.1002/ijc.25429. View

13.

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

14.

Kim J, Wieckowski E, Taylor D, Reichert T, Watkins S, Whiteside T . Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005; 11(3):1010-20. View

15.

Martinez F, Gordon S . The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6:13. PMC: 3944738. DOI: 10.12703/P6-13. View

16.

Biswas S, Mantovani A . Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010; 11(10):889-96. DOI: 10.1038/ni.1937. View

17.

Xiang X, Poliakov A, Liu C, Liu Y, Deng Z, Wang J . Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer. 2009; 124(11):2621-33. PMC: 2757307. DOI: 10.1002/ijc.24249. View

18.

Teng M, Swann J, Koebel C, Schreiber R, Smyth M . Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol. 2008; 84(4):988-93. DOI: 10.1189/jlb.1107774. View

19.

Welters M, Kenter G, de Vos van Steenwijk P, Lowik M, Berends-van der Meer D, Essahsah F . Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A. 2010; 107(26):11895-9. PMC: 2900675. DOI: 10.1073/pnas.1006500107. View

20.

Todaro M, Meraviglia S, Caccamo N, Stassi G, Dieli F . Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells. Oncoimmunology. 2013; 2(9):e25821. PMC: 3825724. DOI: 10.4161/onci.25821. View